Company intelligence / Profile preview

AGC Biologics

Bothell, Washington, United Statesagcbio.com ↗

Ownership: Private
Employees: ~5000
Development stage: Commercial

Overview

AGC Biologics has produced 5 commercial viral vector products and 4 commercial cell therapy products. The company has helped bring 5 different products to market and is responsible for 30% of ex-vivo gene therapy products on the market.

Modalities: Protein-based biologicsmammalian and microbial-based therapeutic proteinsplasmid DNA (pDNA)messenger RNA (mRNA)viral vectors (lentiviral, retroviral, and adeno-associated viral vectors)genetically engineered cellscell therapiesantibody drug conjugates
Industry: Contract Manufacturing Organization

Drug pipeline

1 asset

nalotimagene carmaleucel

Discovery

Indications: Solid tumors

Beyond the preview

Go deeper on AGC Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGC Biologics.

Explore the full profile